PubRank

L Frölich

Author PubWeight™ 54.89‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002 3.88
2 Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004 2.12
3 Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology 2012 1.78
4 Psychosocial work factors and dementia. Occup Environ Med 2004 1.62
5 Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 2008 1.54
6 IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007 1.45
7 [Mild cognitive impairment with predictors of rapid decline]. Dtsch Med Wochenschr 2008 1.39
8 Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res 1998 1.21
9 Effects of arousing emotional scenes on the distribution of visuospatial attention: changes with aging and early subcortical vascular dementia. J Neurol Sci 2004 1.19
10 Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp Neurol 2009 1.17
11 The practice of obtaining approval from medical research ethics committees: a comparison within 12 European countries for a descriptive study on acetylcholinesterase inhibitors in Alzheimer's dementia. Eur J Neurol 2005 1.15
12 Functional imaging of visuospatial processing in Alzheimer's disease. Neuroimage 2002 1.11
13 Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neurosci Lett 1999 1.08
14 A multicenter (1)H-MRS study of the medial temporal lobe in AD and MCI. Neurology 2009 1.05
15 Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J Nutr Health Aging 2009 1.04
16 Differential validity of psychometric tests in dementia of the Alzheimer type. Psychiatry Res 1992 0.98
17 Dementia of the Alzheimer type: effects on the spontaneous EEG described by dipole sources. Psychiatry Res 1993 0.94
18 Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 1995 0.94
19 [The effect of psychosocial factors on risk of dementia]. Fortschr Neurol Psychiatr 2002 0.93
20 White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study. J Neurol Neurosurg Psychiatry 2009 0.92
21 Event-related potentials and psychopharmacology. Cholinergic modulation of P300. Pharmacopsychiatry 1994 0.90
22 Multimodal imaging of residual function and compensatory resource allocation in cortical atrophy: a case study of parietal lobe function in a patient with Huntington's disease. Psychiatry Res 1999 0.90
23 Topography of the quantitative electroencephalogram in dementia of the Alzheimer type: relation to severity of dementia. Psychiatry Res 1991 0.88
24 Multilead quantitative electroencephalogram profile and cognitive evoked potentials (P300) in healthy subjects after a single dose of olanzapine. Psychopharmacology (Berl) 2001 0.87
25 Enhanced ROS-generation in lymphocytes from Alzheimer's patients. Pharmacopsychiatry 2005 0.87
26 A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J Nutr Health Aging 2012 0.85
27 Progression of Alzheimer disease in Europe: data from the European ICTUS study. Curr Alzheimer Res 2012 0.85
28 A comparison of qEEG and HMPAO-SPECT in relation to the clinical severity of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1997 0.83
29 Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? J Neural Transm Suppl 1995 0.83
30 [Creative therapy options for patients with dementia--a systematic review]. Fortschr Neurol Psychiatr 2006 0.83
31 Venlafaxin-associated post-ictal asystole during electroconvulsive therapy. Pharmacopsychiatry 2011 0.82
32 [Attitudes towards predictive genetic testing for Alzheimer's disease]. Z Gerontol Geriatr 2006 0.82
33 Reduced immunoreactivity of adenylyl cyclase in dementia of the Alzheimer type. Neuroreport 1996 0.82
34 Mefloquine-induced paranoid psychosis and subsequent major depression in a 25-year-old student. Pharmacopsychiatry 2002 0.82
35 Apoptosis of CD4+ T and natural killer cells in Alzheimer's disease. Pharmacopsychiatry 2006 0.82
36 Correlation between cognitive brain function and electrical brain activity in dementia of Alzheimer type. J Neural Transm Gen Sect 1995 0.81
37 P3 topography in psychiatry and psychopharmacology. Brain Topogr 1990 0.81
38 The clinical utility of structural neuroimaging with MRI for diagnosis and differential diagnosis of dementia: a memory clinic study. Int J Geriatr Psychiatry 2005 0.81
39 The fuzzy frontier between subjective memory complaints and early dementia. A survey of patient management in German memory clinics. Dement Geriatr Cogn Disord 2004 0.80
40 Decline and preservation of reversal learning abilities and acquisition in the course of senescence. Neurosci Lett 1995 0.80
41 Subclinical hyperthyroidism in dementia and correlation of the metabolic index in FDG-PET. Acta Med Austriaca 2003 0.80
42 Reduced immunoreactivity of type I adenylyl cyclase in the postmortem brains of alcoholics. Alcohol Clin Exp Res 1998 0.79
43 [Dementia and suicide]. Fortschr Neurol Psychiatr 2001 0.78
44 Oxidative-stress associated parameters (lactoferrin, superoxide dismutases) in serum of patients with Alzheimer's disease. Life Sci 1997 0.78
45 Endocrine responses to growth hormone releasing hormone and corticotropin releasing hormone in early-onset Alzheimer's disease. Psychiatry Res 1990 0.78
46 [Attitudes toward dementia management in Germany - Data from the IMPACT survey (Important Perspectives on Alzheimer's Care and Treatment)]. Dtsch Med Wochenschr 2012 0.77
47 Mnestic block syndrome. Cortex 1999 0.77
48 [MCI-plus: mild cognitive impairment with rapid progression. Part I: prevention and therapy]. Dtsch Med Wochenschr 2008 0.77
49 Investigations on the point mutations at nt 5460 of the mtDNA in different neurodegenerative and neuromuscular diseases. Eur Neurol 1996 0.77
50 [Etiology and pathogenesis of Alzheimer dementia]. Wien Med Wochenschr 2002 0.76
51 Alteration of glutamyltranspeptidase binding proteins in postmortem brains of heroin addicts. Alcohol Clin Exp Res 1996 0.76
52 Multimodal imaging of residual function and compensatory resource allocation in cortical atrophy: a case study of parietal lobe function in a patient with Huntington's disease. Psychiatry Res 1998 0.76
53 [Alzheimer's disease versus vascular dementia -- dichotomy or interaction?]. Fortschr Neurol Psychiatr 2005 0.76
54 Brain imaging and neuropsychology in late-onset dementia due to a novel mutation (R93C) of valosin-containing protein. Clin Neuropathol 2007 0.76
55 Imbalance of the Gs and Gi/o function in post-mortem human brain of depressed patients. J Neural Transm Gen Sect 1993 0.76
56 [MCI-plus: mild cognitive impairment with rapid progression. Part II: Biomarkers and research methods]. Dtsch Med Wochenschr 2009 0.76
57 Turning principles into practice in Alzheimer's disease. Int J Clin Pract 2010 0.75
58 First results on the effect of vincristine on brain glucose and energy metabolism in rats. Mech Ageing Dev 1981 0.75
59 Reflection of changes in membrane constituents in various regions of Alzheimer brains to differential scanning thermograms. J Neural Transm Suppl 1990 0.75
60 [Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office]. Fortschr Med Orig 2002 0.75
61 Results from a Phase II Study to Assess the Clinical and Immunological Activity of AFFITOPE® AD02 in Patients with Early Alzheimer's Disease. J Prev Alzheimers Dis 2015 0.75
62 [Early diagnosis and therapy of Alzheimer dementia. Careful documentation prevents degeneration]. MMW Fortschr Med 2002 0.75
63 Regional differences in effects of APOE ε4 on cognitive impairment in non-demented subjects. Dement Geriatr Cogn Disord 2011 0.75
64 Left hemispheric reductions of regional cerebral blood flow (rCBF) correlate with measures of dementia severity in patients with Alzheimer's disease: a SPECT study. Eur Psychiatry 1996 0.75
65 Impairment of G(salpha) function in human brain cortex of Alzheimer's disease: comparison with normal aging. J Neural Transm (Vienna) 2003 0.75
66 [Guidelines on "pharmacotherapy of neurodegenerative dementia": an update]. Nervenarzt 2014 0.75
67 [Importance of the EEG in early and differential diagnosis of dementia of the Alzheimer type]. Fortschr Neurol Psychiatr 1992 0.75
68 Meeting Report: Dementia and stroke: biology of the aging brain. Neurobiol Aging 1987 0.75
69 [Effect of daily living-related cognitive training on attention and memory performance of persons with dementia]. Z Gerontol Geriatr 2002 0.75
70 Increase of optical illusion in demented patients. J Neural Transm Suppl 1998 0.75
71 Glucocorticoid receptors on mononuclear leukocytes in Alzheimer's disease. Psychiatry Res 1990 0.75
72 Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. Phytomedicine 1998 0.75
73 Two cases of primary hyperparathyroidism with depressive and cognitive symptoms. J Nutr Health Aging 2010 0.75
74 [Progressive paralysis: prognostic indications by modern imaging procedures. A case report]. Nervenarzt 1993 0.75
75 [The 12th German Drug Law (AMG) amendment: an obstruction for non-commercial clinical trials?]. Dtsch Med Wochenschr 2007 0.75
76 [Insomnia in the elderly. An under-diagnosed and over-treated syndrome]. Internist (Berl) 2010 0.75